Table 4.
Association between exacerbation, IPF treatment and studied variants.
| MUC5B rs35705950 | Antifibrotic treatment | Non-IPF treatment | ||||
|---|---|---|---|---|---|---|
| Carriage T | Genotype GG | Carriage T | Genotype GG | |||
| n = 93 | n = 74 | n = 23 | n = 20 | |||
| Yes | 20 (21.5%) | 17 (23.0%) | 0.821 | 7 (30.4%) | 5 (25.0%) | 0.691 |
| Number of exacerbations | ||||||
| 1 | 13 (65.0%) | 12 (70.6%) | 0.396 | 5 (71.4%) | 3 (60.0%) | 0.387 |
| 2 | 6 (30.0%) | 4 (23.5%) | 1 (14.3%) | 2 (40.0%) | ||
| 3 | 1 (5.0%) | 0 (0.0%) | 1 (14.3%) | 0 (0.0%) | ||
| 4 | 0 (0.0%) | 1 (5.9%) | 0 (0.0%) | 0 (0.0%) | ||
| DSP rs2076295 | Carriage G | Genotype TT | Carriage G | Genotype TT | ||
| 97 | 70 | 26 | 17 | |||
| Yes | 20 (20.6%) | 17 (24.3%) | 0.574 | 6 (23.1%) | 6 (35.3%) | 0.385 |
| Number of exacerbations | ||||||
| 1 | 12 (60.0%) | 13 (76.5%) | 0.396 | 5 (83.3%) | 3 (50.0%) | 0.328 |
| 2 | 6 (30.0%) | 4 (23.5%) | 1 (16.7%) | 2 (33.3%) | ||
| 3 | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) | 1 (16.7%) | ||
| 4 | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
IPF, idiopathic pulmonary fibrosis.